These findings revealed that the abnormal expression of SCD in specific cancers may stem from genetic alterations and promoter hypermethylation, providing a deeper understanding of PRAD tumorigenesis and guiding potential treatment strategy. This evidence concerns the gene SCD and prostate adenocarcinoma.